Alex R. Schuurman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alex R. Schuurman has a total of 276 co-authors. Here are the top co-authors by number of shared publications:
- Tom D. Y. Reijnders
Center for Infection and Molecular Medicine, Amsterdam University Medical Center, University of Amsterdam, 1105AZ Amsterdam, The Netherlands
7 shared publications Tom van der Poll
Centre for Infection and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
7 shared publications- Joe M. Butler
Centre for Infection and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
6 shared publications - Tom van der Poll
Center of Experimental and Molecular Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
6 shared publications W. Joost Wiersinga
Centre for Infection and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
6 shared publications- Hessel Peters-Sengers
Centre for Infection and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
5 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Evaluation of the Strongyloides stercoralis VirClia IgG monotest for the diagnosis of strongyloidiasis in a diverse clinical cohort
Strongyloides stercoralis is an intestinal nematode with the capacity for lifelong autoinfection and potentially fatal hyperinfection in immunocompromised patients. In non-or-low-endemic settings, serology is central to diagnosis, but most current assays are batch-dependent, labor-intensive, and restricted to referral centers. There is an unmet need for a rapid, robust, random-access screening test. To evaluate the clinical and diagnostic performance of the Strongyloides VirClia IgG monotest, a CE-IVD chemiluminescent immunoassay (Vircell), in a non-endemic setting, we tested stored sera from microbiologically confirmed strongyloidiasis cases, external quality assessment samples, healthy controls, and a broad disease-control panel covering viral, bacterial, protozoal, and other helminth infections. All samples were tested on the VirClia Lotus analyzer and compared with a previously published in-house enzyme-linked immunosorbent assay. A total of 69 confirmed cases and 210 controls (171 disease controls, 39 healthy controls) were analyzed. Sensitivity was 98.6% (68/69; 95% confidence interval [CI] 92.2%–99.7%), and specificity was 98.1% (206/210; 95% CI 95.2%–99.3%). The area under the receiver operating characteristic curve was 0.985 (95% CI 0.961–1.000), with a high positive (LR+ = 52) and near-perfect negative (LR− = 0.015) likelihood ratio. All four false positives occurred in patients with concurrent parasitic infections; cross-reactivity was otherwise only sporadic. Inter-laboratory comparison showed comparable results. The Strongyloides VirClia IgG monotest showed excellent diagnostic accuracy in a diverse, clinically relevant cohort. Combined with its random-access format and short turnaround time, the assay is well suited as a first-line screening tool for strongyloidiasis in non-endemic settings. IMPORTANCE: Strongyloides stercoralis is an intestinal roundworm with a substantial global disease burden. Infection is typically chronic and largely asymptomatic, but in severely immunocompromised patients—such as those on immunosuppressive therapy or with hematological malignancies—it can progress to a hyperinfection syndrome, carrying a high risk of complications and mortality. As immunosuppressant use rises and treatment options for hematological malignancies expand, the at-risk population for Strongyloides hyperinfection syndrome continues to grow. Medical microbiological laboratories therefore need a reliable and sensitive strongyloidiasis screening assay with a short turnaround time. In this study, we show that the S. stercoralis VirClia IgG monotest can meet this need, with high diagnostic accuracy in a relevant and diverse clinical cohort. These findings support adoption by other laboratories after local verification, without the need for an extensive in-house validation as presented here.
- 2 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
Open AccessEvaluation of the Strongyloides stercoralis VirClia IgG monotest for the diagnosis of strongyloidiasis in a diverse clinical cohort
Strongyloides stercoralis is an intestinal nematode with the capacity for lifelong autoinfection and potentially fatal hyperinfection in immunocompromised patients. In non-or-low-endemic settings, serology is central to diagnosis, but most current assays are batch-dependent, labor-intensive, and restricted to referral centers. There is an unmet need for a rapid, robust, random-access screening test. To evaluate the clinical and diagnostic performance of the Strongyloides VirClia IgG monotest, a CE-IVD chemiluminescent immunoassay (Vircell), in a non-endemic setting, we tested stored sera from microbiologically confirmed strongyloidiasis cases, external quality assessment samples, healthy controls, and a broad disease-control panel covering viral, bacterial, protozoal, and other helminth infections. All samples were tested on the VirClia Lotus analyzer and compared with a previously published in-house enzyme-linked immunosorbent assay. A total of 69 confirmed cases and 210 controls (171 disease controls, 39 healthy controls) were analyzed. Sensitivity was 98.6% (68/69; 95% confidence interval [CI] 92.2%–99.7%), and specificity was 98.1% (206/210; 95% CI 95.2%–99.3%). The area under the receiver operating characteristic curve was 0.985 (95% CI 0.961–1.000), with a high positive (LR+ = 52) and near-perfect negative (LR− = 0.015) likelihood ratio. All four false positives occurred in patients with concurrent parasitic infections; cross-reactivity was otherwise only sporadic. Inter-laboratory comparison showed comparable results. The Strongyloides VirClia IgG monotest showed excellent diagnostic accuracy in a diverse, clinically relevant cohort. Combined with its random-access format and short turnaround time, the assay is well suited as a first-line screening tool for strongyloidiasis in non-endemic settings. IMPORTANCE: Strongyloides stercoralis is an intestinal roundworm with a substantial global disease burden. Infection is typically chronic and largely asymptomatic, but in severely immunocompromised patients—such as those on immunosuppressive therapy or with hematological malignancies—it can progress to a hyperinfection syndrome, carrying a high risk of complications and mortality. As immunosuppressant use rises and treatment options for hematological malignancies expand, the at-risk population for Strongyloides hyperinfection syndrome continues to grow. Medical microbiological laboratories therefore need a reliable and sensitive strongyloidiasis screening assay with a short turnaround time. In this study, we show that the S. stercoralis VirClia IgG monotest can meet this need, with high diagnostic accuracy in a relevant and diverse clinical cohort. These findings support adoption by other laboratories after local verification, without the need for an extensive in-house validation as presented here.
- Open Access
- 9 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Programmed death-ligand 1 links with inflammatory and endothelial activation in pneumonia
Background: Soluble programmed death-ligand 1 (sPD-L1) is often considered a marker of immunosuppression, proposed to reflect PD-1/PD-L1 signalling on immune cells. We aimed to investigate this premise and characterised plasma sPD-L1-associated immune responses in community-acquired pneumonia (CAP). Methods: Plasma sPD-L1 and 60 biomarkers reflecting inflammation, vascular response, coagulation and cytokine/chemokine release were measured in CAP patients within 24 h after admission to a general hospital ward. Associations were analysed using both univariate and multivariable models. In patient subgroups, immune cell PD-1/PD-L1 was assessed by spectral flow cytometry and blood transcriptomes by RNA sequencing. Results: CAP patients (n=226) were stratified into tertiles based on sPD-L1 levels. Admission disease severity scores were similar across groups. In-hospital mortality only occurred in the highest sPD-L1 tertile and in a continuous analysis sPD-L1 independently predicted 28-day mortality (overall 4.4%). Higher sPD-L1 was linked to plasma biomarker changes indicating increased systemic inflammation, cytokine release, and endothelial activation. sPD-L1 did not correlate with PD-L1 expression on monocytes or dendritic cells, nor with PD-L1 gene expression in whole blood. sPD-L1 did not associate with immunosuppression markers (IL-10, monocyte HLA-DR, and PD-1 on T cells). In patients with high sPD-L1, blood transcriptomes showed enrichment of haemostasis, endothelial activation, and systemic inflammation, but not of programmed cell death pathways. Conclusions: In patients hospitalised with CAP plasma sPD-L1 does not reflect immune cell PD-L1 expression or immunosuppression, but rather systemic inflammation and endothelial activation.
- 9 July 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessProgrammed death-ligand 1 links with inflammatory and endothelial activation in pneumonia
Background: Soluble programmed death-ligand 1 (sPD-L1) is often considered a marker of immunosuppression, proposed to reflect PD-1/PD-L1 signalling on immune cells. We aimed to investigate this premise and characterised plasma sPD-L1-associated immune responses in community-acquired pneumonia (CAP). Methods: Plasma sPD-L1 and 60 biomarkers reflecting inflammation, vascular response, coagulation and cytokine/chemokine release were measured in CAP patients within 24 h after admission to a general hospital ward. Associations were analysed using both univariate and multivariable models. In patient subgroups, immune cell PD-1/PD-L1 was assessed by spectral flow cytometry and blood transcriptomes by RNA sequencing. Results: CAP patients (n=226) were stratified into tertiles based on sPD-L1 levels. Admission disease severity scores were similar across groups. In-hospital mortality only occurred in the highest sPD-L1 tertile and in a continuous analysis sPD-L1 independently predicted 28-day mortality (overall 4.4%). Higher sPD-L1 was linked to plasma biomarker changes indicating increased systemic inflammation, cytokine release, and endothelial activation. sPD-L1 did not correlate with PD-L1 expression on monocytes or dendritic cells, nor with PD-L1 gene expression in whole blood. sPD-L1 did not associate with immunosuppression markers (IL-10, monocyte HLA-DR, and PD-1 on T cells). In patients with high sPD-L1, blood transcriptomes showed enrichment of haemostasis, endothelial activation, and systemic inflammation, but not of programmed cell death pathways. Conclusions: In patients hospitalised with CAP plasma sPD-L1 does not reflect immune cell PD-L1 expression or immunosuppression, but rather systemic inflammation and endothelial activation.
- Open Access
- 28 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10461
Role of Myeloid Cell Glucose Transporter 1 in the Host Response During Pneumonia Caused by Streptococcus pneumoniae
During infection, myeloid cells are subjected to a fast increase in energy demand. Glucose transporter 1 (GLUT1) is a key mediator of glucose metabolism, especially for glycolysis. The present study aimed to investigate GLUT1 expression in monocytes and neutrophils from patients with community-acquired pneumonia (CAP) and to determine the functional role of GLUT1 in the responsiveness during pneumonia evoked in mice by Streptococcus (S.) pneumoniae, the most common causative pathogen in CAP. GLUT1 expression in monocytes and neutrophils of patients and controls was determined by RNA sequencing and flow cytometry analysis. Myeloid cell-specific GLUT1-deficient mice and controls were intranasally infected with S. pneumoniae, after which bacterial loads, lung pathology, and cytokine levels were analyzed. GLUT1 gene expression was upregulated in monocytes from CAP patients in comparison to matched subjects without infection, and protein expression was increased upon ex vivo activation. In neutrophils, GLUT1 mRNA levels were significantly upregulated in CAP patients, but protein levels were not altered. Surprisingly, myeloid-specific GLUT1-deficient mice displayed an unaltered host response during pneumococcal pneumonia. These data suggest that GLUT1 may contribute to immune responses of myeloid cells during CAP, but that its role may be superseded by other mechanisms during pneumococcal pneumonia.
- 28 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10461
Open AccessRole of Myeloid Cell Glucose Transporter 1 in the Host Response During Pneumonia Caused by Streptococcus pneumoniae
During infection, myeloid cells are subjected to a fast increase in energy demand. Glucose transporter 1 (GLUT1) is a key mediator of glucose metabolism, especially for glycolysis. The present study aimed to investigate GLUT1 expression in monocytes and neutrophils from patients with community-acquired pneumonia (CAP) and to determine the functional role of GLUT1 in the responsiveness during pneumonia evoked in mice by Streptococcus (S.) pneumoniae, the most common causative pathogen in CAP. GLUT1 expression in monocytes and neutrophils of patients and controls was determined by RNA sequencing and flow cytometry analysis. Myeloid cell-specific GLUT1-deficient mice and controls were intranasally infected with S. pneumoniae, after which bacterial loads, lung pathology, and cytokine levels were analyzed. GLUT1 gene expression was upregulated in monocytes from CAP patients in comparison to matched subjects without infection, and protein expression was increased upon ex vivo activation. In neutrophils, GLUT1 mRNA levels were significantly upregulated in CAP patients, but protein levels were not altered. Surprisingly, myeloid-specific GLUT1-deficient mice displayed an unaltered host response during pneumococcal pneumonia. These data suggest that GLUT1 may contribute to immune responses of myeloid cells during CAP, but that its role may be superseded by other mechanisms during pneumococcal pneumonia.
- Top Cited Papers
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (8) , 973-986
The Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia
Rationale: The plasma lipidome has the potential to reflect many facets of the host status during severe infection. Previous work is limited to specific lipid groups or was focused on lipids as prognosticators. Objectives: To map the plasma lipidome during sepsis due to community-acquired pneumonia (CAP) and determine the disease specificity and associations with clinical features. Methods: We analyzed 1,833 lipid species across 33 classes in 169 patients admitted to the ICU with sepsis due to CAP, 51 noninfected ICU patients, and 48 outpatient controls. In a paired analysis, we reanalyzed patients still in the ICU 4 days after admission (n = 82). Measurements and Main Results: A total of 58% of plasma lipids were significantly lower in patients with CAP-attributable sepsis compared with outpatient controls (6% higher, 36% not different). We found strong lipid class–specific associations with disease severity, validated across two external cohorts, and inflammatory biomarkers, in which triacylglycerols, cholesterol esters, and lysophospholipids exhibited the strongest associations. A total of 36% of lipids increased over time, and stratification by survival revealed diverging lipid recovery, which was confirmed in an external cohort; specifically, a 10% increase in cholesterol ester levels was related to a lower odds ratio (0.84; P = 0.006) for 30-day mortality (absolute mortality, 18 of 82). Comparison with noninfected ICU patients delineated a substantial common illness response (57.5%) and a distinct lipidomic signal for patients with CAP-attributable sepsis (37%). Conclusions: Patients with sepsis due to CAP exhibit a time-dependent and partially disease-specific shift in their plasma lipidome that correlates with disease severity and systemic inflammation and is associated with higher mortality.
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (8) , 973-986
Top Cited PapersThe Plasma Lipidomic Landscape in Patients with Sepsis due to Community-acquired Pneumonia
Rationale: The plasma lipidome has the potential to reflect many facets of the host status during severe infection. Previous work is limited to specific lipid groups or was focused on lipids as prognosticators. Objectives: To map the plasma lipidome during sepsis due to community-acquired pneumonia (CAP) and determine the disease specificity and associations with clinical features. Methods: We analyzed 1,833 lipid species across 33 classes in 169 patients admitted to the ICU with sepsis due to CAP, 51 noninfected ICU patients, and 48 outpatient controls. In a paired analysis, we reanalyzed patients still in the ICU 4 days after admission (n = 82). Measurements and Main Results: A total of 58% of plasma lipids were significantly lower in patients with CAP-attributable sepsis compared with outpatient controls (6% higher, 36% not different). We found strong lipid class–specific associations with disease severity, validated across two external cohorts, and inflammatory biomarkers, in which triacylglycerols, cholesterol esters, and lysophospholipids exhibited the strongest associations. A total of 36% of lipids increased over time, and stratification by survival revealed diverging lipid recovery, which was confirmed in an external cohort; specifically, a 10% increase in cholesterol ester levels was related to a lower odds ratio (0.84; P = 0.006) for 30-day mortality (absolute mortality, 18 of 82). Comparison with noninfected ICU patients delineated a substantial common illness response (57.5%) and a distinct lipidomic signal for patients with CAP-attributable sepsis (37%). Conclusions: Patients with sepsis due to CAP exhibit a time-dependent and partially disease-specific shift in their plasma lipidome that correlates with disease severity and systemic inflammation and is associated with higher mortality.
- Open Access
- 22 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (4)
The shifting lipidomic landscape of blood monocytes and neutrophils during pneumonia
The lipidome of immune cells during infection has remained unexplored, although evidence of the importance of lipids in the context of immunity is mounting. In this study, we performed untargeted lipidomic analysis of blood monocytes and neutrophils from patients hospitalized for pneumonia and age- and sex-matched noninfectious control volunteers. We annotated 521 and 706 lipids in monocytes and neutrophils, respectively, which were normalized to an extensive set of internal standards per lipid class. The cellular lipidomes were profoundly altered in patients, with both common and distinct changes between the cell types. Changes involved every level of the cellular lipidome: differential lipid species, class-wide shifts, and altered saturation patterns. Overall, differential lipids were mainly less abundant in monocytes and more abundant in neutrophils from patients. One month after hospital admission, lipidomic changes were fully resolved in monocytes and partially in neutrophils. Integration of lipidomic and concurrently collected transcriptomic data highlighted altered sphingolipid metabolism in both cell types. Inhibition of ceramide and sphingosine-1-phosphate synthesis in healthy monocytes and neutrophils resulted in blunted cytokine responses upon stimulation with lipopolysaccharide. These data reveal major lipidomic remodeling in immune cells during infection, and link the cellular lipidome to immune functionality.
- 22 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (4)
Open AccessThe shifting lipidomic landscape of blood monocytes and neutrophils during pneumonia
The lipidome of immune cells during infection has remained unexplored, although evidence of the importance of lipids in the context of immunity is mounting. In this study, we performed untargeted lipidomic analysis of blood monocytes and neutrophils from patients hospitalized for pneumonia and age- and sex-matched noninfectious control volunteers. We annotated 521 and 706 lipids in monocytes and neutrophils, respectively, which were normalized to an extensive set of internal standards per lipid class. The cellular lipidomes were profoundly altered in patients, with both common and distinct changes between the cell types. Changes involved every level of the cellular lipidome: differential lipid species, class-wide shifts, and altered saturation patterns. Overall, differential lipids were mainly less abundant in monocytes and more abundant in neutrophils from patients. One month after hospital admission, lipidomic changes were fully resolved in monocytes and partially in neutrophils. Integration of lipidomic and concurrently collected transcriptomic data highlighted altered sphingolipid metabolism in both cell types. Inhibition of ceramide and sphingosine-1-phosphate synthesis in healthy monocytes and neutrophils resulted in blunted cytokine responses upon stimulation with lipopolysaccharide. These data reveal major lipidomic remodeling in immune cells during infection, and link the cellular lipidome to immune functionality.
- Open Access
- 27 September 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (7) , 102213
Platelets of COVID-19 patients display mitochondrial dysfunction, oxidative stress, and energy metabolism failure compatible with cell death
- 27 September 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (7) , 102213
Open AccessPlatelets of COVID-19 patients display mitochondrial dysfunction, oxidative stress, and energy metabolism failure compatible with cell death
- Open Access
- 6 July 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (1) , 2300011
Age-related changes in plasma biomarkers and their association with mortality in COVID-19
Background: Coronavirus disease 2019 (COVID-19)-induced mortality occurs predominantly in older patients. Several immunomodulating therapies seem less beneficial in these patients. The biological substrate behind these observations is unknown. The aim of this study was to obtain insight into the association between ageing, the host response and mortality in patients with COVID-19.Methods: We determined 43 biomarkers reflective of alterations in four pathophysiological domains: endothelial cell and coagulation activation, inflammation and organ damage, and cytokine and chemokine release. We used mediation analysis to associate ageing-driven alterations in the host response with 30-day mortality. Biomarkers associated with both ageing and mortality were validated in an intensive care unit and external cohort.Results: 464 general ward patients with COVID-19 were stratified according to age decades. Increasing age was an independent risk factor for 30-day mortality. Ageing was associated with alterations in each of the host response domains, characterised by greater activation of the endothelium and coagulation system and stronger elevation of inflammation and organ damage markers, which was independent of an increase in age-related comorbidities. Soluble tumour necrosis factor receptor 1, soluble triggering receptor expressed on myeloid cells 1 and soluble thrombomodulin showed the strongest correlation with ageing and explained part of the ageing-driven increase in 30-day mortality (proportion mediated: 13.0%, 12.9% and 12.6%, respectively).Conclusions: Ageing is associated with a strong and broad modification of the host response to COVID-19, and specific immune changes likely contribute to increased mortality in older patients. These results may provide insight into potential age-specific immunomodulatory targets in COVID-19.
- 6 July 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (1) , 2300011
Open AccessAge-related changes in plasma biomarkers and their association with mortality in COVID-19
Background: Coronavirus disease 2019 (COVID-19)-induced mortality occurs predominantly in older patients. Several immunomodulating therapies seem less beneficial in these patients. The biological substrate behind these observations is unknown. The aim of this study was to obtain insight into the association between ageing, the host response and mortality in patients with COVID-19.Methods: We determined 43 biomarkers reflective of alterations in four pathophysiological domains: endothelial cell and coagulation activation, inflammation and organ damage, and cytokine and chemokine release. We used mediation analysis to associate ageing-driven alterations in the host response with 30-day mortality. Biomarkers associated with both ageing and mortality were validated in an intensive care unit and external cohort.Results: 464 general ward patients with COVID-19 were stratified according to age decades. Increasing age was an independent risk factor for 30-day mortality. Ageing was associated with alterations in each of the host response domains, characterised by greater activation of the endothelium and coagulation system and stronger elevation of inflammation and organ damage markers, which was independent of an increase in age-related comorbidities. Soluble tumour necrosis factor receptor 1, soluble triggering receptor expressed on myeloid cells 1 and soluble thrombomodulin showed the strongest correlation with ageing and explained part of the ageing-driven increase in 30-day mortality (proportion mediated: 13.0%, 12.9% and 12.6%, respectively).Conclusions: Ageing is associated with a strong and broad modification of the host response to COVID-19, and specific immune changes likely contribute to increased mortality in older patients. These results may provide insight into potential age-specific immunomodulatory targets in COVID-19.
- Open Access
Inflammatory and glycolytic programs underpin a primed blood neutrophil state in patients with pneumonia